Research reports from Morningstar & Argus help you make better investment decisions. Leverage these to understand future stock performance and identify high performing investment ideas. You can also ...

The S&P 500 ticked lower by less than 0.1% on Friday, Feb. 14, as retail sales data revealed a retreat in consumer spending ...

Truist notes that AnaptysBio (ANAB) reported the “much anticipated” results of its Phase 2b trial of rosnilimab for ...

Here is how AnaptysBio, Inc. (ANAB) and AtriCure (ATRC) have performed compared to their sector so far this year.

H.C. Wainwright analyst Emily Bodnar increased the price target on AnaptysBio (NASDAQ:ANAB) shares to $22.00, up from the previous $19.00, while maintaining a Neutral rating on the stock. According to ...

AnaptysBio (ANAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Global ISO experts, Amtivo Group, is delighted to announce the relaunch of its website dedicated to ISO 9001, together with a ...

AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ...

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placeboAchieved statistical significance on key secondary ...